Frederick Lansigan1, Steven M Horwitz2, Lauren C Pinter-Brown3, Kenneth R Carson4, Andrei R Shustov5, Steven T Rosen6, Barbara Pro7, Eric D Hsi8, Massimo Federico9, Christian Gisselbrecht10, Marc Schwartz11, Lisa A Bellm12, Mark Acosta13, Francine M Foss14. 1. Dartmouth Hitchcock Medical Center, Hanover, NH. 2. Memorial Sloan-Kettering Cancer Center, New York, NY. 3. University of California Irvine, Irvine, CA. 4. Washington University School of Medicine, St. Louis, MO. 5. Fred Hutchinson Cancer Research Center, Seattle, WA. 6. City of Hope, Duarte, CA. 7. Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL. 8. Cleveland Clinic, Cleveland, OH. 9. University of Modena and Reggio Emilia, Modena, Italy. 10. Hôpital Saint Louis, Paris, France. 11. MS Biostatistics, LLC, Clermont, FL. 12. MedNet Solutions, Minnetonka, MN. 13. Acrotech Biopharma, Irvine, CA. 14. Yale University, New Haven, CT. Electronic address: Francine.foss@yale.edu.
Abstract
INTRODUCTION: We examined patient characteristics, treatments, and outcomes of patients with transformed mycosis fungoides (tMF) from COMPLETE: a large, multicenter, prospective cohort study of peripheral T-cell lymphoma patients in the United States. METHODS: Patients with tMF were enrolled in COMPLETE at the time of transformation. For this analysis, we identified patients with tMF with completed baseline, treatment, and follow-up records. Median survival was assessed using Kaplan-Meier methodology. RESULTS: Of the 499 patients enrolled in COMPLETE, 17 had tMF. Median age was 61; 53% were male, 9 had elevated lactate dehydrogenase, and 9 had lymph node involvement. Approximately one-quarter of the patients were African American and 47% had CD30+ disease. Median time to transformation was 53 months. All patients received systemic therapy, with 19% receiving concomitant radiotherapy. Most patients (87%) received single agents, including liposomal doxorubicin, pralatrexate, and gemcitabine. Eight patients (50%) had reported responses to therapy. Median survival was 18 months. One- and 2-year survival rates were 56% and 44%, respectively. CONCLUSIONS: tMF often expresses CD30 and presents with lymph node involvement. Responses have been seen with single agents, but survival remains poor. Novel treatment approaches are urgently needed to improve outcomes.
INTRODUCTION: We examined patient characteristics, treatments, and outcomes of patients with transformed mycosis fungoides (tMF) from COMPLETE: a large, multicenter, prospective cohort study of peripheral T-cell lymphoma patients in the United States. METHODS: Patients with tMF were enrolled in COMPLETE at the time of transformation. For this analysis, we identified patients with tMF with completed baseline, treatment, and follow-up records. Median survival was assessed using Kaplan-Meier methodology. RESULTS: Of the 499 patients enrolled in COMPLETE, 17 had tMF. Median age was 61; 53% were male, 9 had elevated lactate dehydrogenase, and 9 had lymph node involvement. Approximately one-quarter of the patients were African American and 47% had CD30+ disease. Median time to transformation was 53 months. All patients received systemic therapy, with 19% receiving concomitant radiotherapy. Most patients (87%) received single agents, including liposomal doxorubicin, pralatrexate, and gemcitabine. Eight patients (50%) had reported responses to therapy. Median survival was 18 months. One- and 2-year survival rates were 56% and 44%, respectively. CONCLUSIONS: tMF often expresses CD30 and presents with lymph node involvement. Responses have been seen with single agents, but survival remains poor. Novel treatment approaches are urgently needed to improve outcomes.
Authors: B Vergier; A de Muret; M Beylot-Barry; L Vaillant; D Ekouevi; G Chene; A Carlotti; N Franck; P Dechelotte; P Souteyrand; P Courville; P Joly; M Delaunay; M Bagot; F Grange; S Fraitag; J Bosq; T Petrella; A Durlach; A De Mascarel; J P Merlio; J Wechsler Journal: Blood Date: 2000-04-01 Impact factor: 22.113
Authors: Julia J Scarisbrick; H Miles Prince; Maarten H Vermeer; Pietro Quaglino; Steven Horwitz; Pierluigi Porcu; Rudolf Stadler; Gary S Wood; Marie Beylot-Barry; Anne Pham-Ledard; Francine Foss; Michael Girardi; Martine Bagot; Laurence Michel; Maxime Battistella; Joan Guitart; Timothy M Kuzel; Maria Estela Martinez-Escala; Teresa Estrach; Evangelia Papadavid; Christina Antoniou; Dimitis Rigopoulos; Vassilki Nikolaou; Makoto Sugaya; Tomomitsu Miyagaki; Robert Gniadecki; José Antonio Sanches; Jade Cury-Martins; Denis Miyashiro; Octavio Servitje; Cristina Muniesa; Emilio Berti; Francesco Onida; Laura Corti; Emilia Hodak; Iris Amitay-Laish; Pablo L Ortiz-Romero; Jose L Rodríguez-Peralto; Robert Knobler; Stefanie Porkert; Wolfgang Bauer; Nicola Pimpinelli; Vieri Grandi; Richard Cowan; Alain Rook; Ellen Kim; Alessandro Pileri; Annalisa Patrizi; Ramon M Pujol; Henry Wong; Kelly Tyler; Rene Stranzenbach; Christiane Querfeld; Paolo Fava; Milena Maule; Rein Willemze; Felicity Evison; Stephen Morris; Robert Twigger; Rakhshandra Talpur; Jinah Kim; Grant Ognibene; Shufeng Li; Mahkam Tavallaee; Richard T Hoppe; Madeleine Duvic; Sean J Whittaker; Youn H Kim Journal: J Clin Oncol Date: 2015-10-05 Impact factor: 44.544
Authors: Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl Journal: J Clin Oncol Date: 2007-01-22 Impact factor: 44.544
Authors: H Miles Prince; Youn H Kim; Steven M Horwitz; Reinhard Dummer; Julia Scarisbrick; Pietro Quaglino; Pier Luigi Zinzani; Pascal Wolter; Jose A Sanches; Pablo L Ortiz-Romero; Oleg E Akilov; Larisa Geskin; Judith Trotman; Kerry Taylor; Stephane Dalle; Michael Weichenthal; Jan Walewski; David Fisher; Brigitte Dréno; Rudolf Stadler; Tatyana Feldman; Timothy M Kuzel; Yinghui Wang; Maria Corinna Palanca-Wessels; Erin Zagadailov; William L Trepicchio; Wenwen Zhang; Hui-Min Lin; Yi Liu; Dirk Huebner; Meredith Little; Sean Whittaker; Madeleine Duvic Journal: Lancet Date: 2017-06-07 Impact factor: 79.321
Authors: Kenneth R Carson; Steven M Horwitz; Lauren C Pinter-Brown; Steven T Rosen; Barbara Pro; Eric D Hsi; Massimo Federico; Christian Gisselbrecht; Marc Schwartz; Lisa A Bellm; Mark A Acosta; Andrei R Shustov; Ranjana H Advani; Tatyana A Feldman; Mary Jo Lechowicz; Sonali M Smith; Frederick Lansigan; Anil Tulpule; Michael D Craig; John P Greer; Brad S Kahl; Joseph W Leach; Neil Morganstein; Carla Casulo; Steven I Park; Francine M Foss Journal: Cancer Date: 2016-12-02 Impact factor: 6.860